Advancing trial design in progressive multiple sclerosis

Abstract

Get full access to this article

View all access options for this article.

References

Montalban

Hauser

Kappos

Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376: 209–220.

FDA approves new drug to treat multiple sclerosis. First drug approved for primary progressive MS, https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm549325.htm (accessed 29 March 2017).

Sormani

Bruzzi

MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomised trials. Lancet Neurol 2013; 12: 669–676.

Fox

Thompson

Baker

Setting a research agenda for progressive multiple sclerosis: The international collaborative on progressive MS. Mult Scler 2012; 18: 1534–1540.

Mahad

Trapp

Lassmann

Pathological mechanisms in progressive MS. Lancet Neurol 2015; 14: 183–193.

Chataway

Schuerer

Alsanousi

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet 2014; 383: 2213–2221.